Federal Judge Blocks Colorado's First-in-Nation Price Cap on Amgen's Arthritis Drug Enbrel
核心洞察
A federal judge granted Amgen a preliminary injunction blocking Colorado from enforcing a $600 per-dose price cap on the arthritis biologic Enbrel.
The ruling found that state-mandated price caps on patented drugs are preempted by federal patent law and violate due process protections.
Colorado's Prescription Drug Affordability Review Board had capped the annual cost at $31,200, a roughly 70% reduction from prevailing prices.
A United States federal judge has definitively blocked the State of Colorado from enforcing a groundbreaking price cap on Amgen's blockbuster arthritis medication Enbrel, delivering a major victory to the pharmaceutical industry and halting a first-in-the-nation attempt by a state government to forcibly mandate lower prescription costs for patented biological therapies.
On July 1, 2026, Chief Judge Daniel Domenico of the US District Court for the District of Colorado granted a preliminary injunction requested by multinational pharmaceutical giant Amgen. The ruling legally suspends the actions of the Colorado Prescription Drug Affordability Review Board (PDAB), which had recently voted to cap the price of Enbrel.
The $31,000 Mandate Blocked
Enbrel, utilized globally to treat severe autoimmune diseases including rheumatoid arthritis (搜索) and plaque psoriasis (搜索), generated over $2.23 billion in global sales for Amgen in 2025. In the United States, the drug's annual list price frequently exceeds $100,000 per patient.
In October 2025, following extensive analysis, the Colorado board deemed the drug "unaffordable" and established an upper payment limit (UPL) of exactly $600 per 50-milligram weekly dose. This mandate effectively capped the annual cost at $31,200 — a massive 70 percent reduction from typical prevailing prices — which was slated to take effect on January 1, 2027.
The Legal Foundation
Amgen successfully argued that the state-mandated cap violated federal patent law, infringed upon constitutional due process rights, and interfered with interstate commerce. Judge Domenico's opinion was unambiguous: for patent-protected drugs like Enbrel, price caps are "preempted by federal law."
"Amgen is correct that the development of the new medications many of us benefit from requires that profits from the few successful ones be large enough to cover not only their own development, but that of dozens of failed experiments," the judge wrote. He suggested that if states wish to lower costs, they must utilize subsidies or voluntary negotiations, much like the federal Medicare program, rather than deploying blunt legislative price controls.
Judge Domenico further noted that Amgen would face immediate, irreparable harm to its revenue stream and leverage in national negotiations with wholesalers if the state cap were enforced.
Broader Implications for State Drug Pricing Efforts
The ruling carries significant precedential weight. Several other states, including Maryland and Washington, have established similar drug affordability review boards. This decision severely limits their authority to unilaterally impose price ceilings on patented medications.
The creation of the Colorado PDAB in 2021 was a direct political response to voter frustration over the lack of competition in the biologic drug market. While biosimilar alternatives have been developed and approved by regulatory agencies, aggressive patent litigation by Amgen has effectively blocked these cheaper competitors from entering the US market until at least 2029. The board was designed to artificially introduce price pressure where the free market, constrained by patents, had failed to do so. With this tool now legally neutralized by the federal judiciary, consumer advocates are left with few immediate options to curb escalating pharmacy bills.
Following the ruling, a spokesperson for the Colorado Division of Insurance declined to comment on pending litigation, while Amgen shares remained stable. As the legal battle likely advances to appellate courts, the core structural reality of the pharmaceutical market remains unchanged: the legal rights of patent holders definitively supersede localized attempts to mandate public affordability.